tbuckley/cabot-search huggingface dataset:
Heterogeneous <i>HER2</i> Amplification—a New Clinical Category of HER2-Positive Breast Cancer?
Authors: Alicia F.C. Okines, Nicholas C. Turner
Journal: Cancer Discovery (2021)

Abstract Summary: HER2 amplification heterogeneity is associated with resistance to trastuzumab emtansine in the neoadjuvant setting, emphasizing the importance of assessing whether heterogeneous HER2-positive cancers require different treatment pathways. See related article by Metzger Filho et al., p. 2474.
1325P Checkpoint inhibitor monotherapy in potentially study-eligible or non-study-eligible NSCLC patients in the German CRISP registry real-world cohort (AIO-TRK-0315)
Authors: F. Griesinger, M. Sebastian, W. Brückl, H-D. Hummel, B. Jaeschke, J. Kern, C. Schumann, C. Wesseler, M. Jänicke, A. Fleitz, S. Zacharias, A. Hipper, A. Groth, W. Weichert, S. Dörfel, V. Petersen, J. Schröder, J. Wilke, W.E.E. Eberhardt, M. Thomas
Journal: Annals of Oncology (2021)
The impact of distractions on intracortical brain–computer interface control of a robotic arm
Authors: Michael D. Guthrie, Angelica J Herrera, John E. Downey, Lucas J. Brane, Michael L. Boninger, Jennifer L. Collinger
Journal: Brain-Computer Interfaces (2021)

The objective of the study was to evaluate the impact of distractions on intracortical brain–computer interface (BCI) performance. Two individuals with tetraplegia had microelectrode arrays implanted into their motor cortex. Each used a BCI to move a robotic arm between two targets as quickly as possible, performed alone and with distractions. Performance outcomes were similar across conditions, except for a drop in the median path efficiency in the motor action distraction for Subject P2 (p = 0.033, Mann–Whitney U-test). Other distraction conditions resulted in intermittent impairments in performance, but were not statistically different from the no distraction condition. Both subjects rated the overall difficulty of the task with and without distractions as low. Consistent levels of BCI performance were mirrored by small differences in neural firing rates across conditions, demonstrating that experienced BCI users can maintain performance on a simple reaching task under these various conditions.
Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial
Authors: V. Ratziu, L. de Guevara, R. Safadi, F. Poordad, F. Fuster, J. Flores-Figueroa, M. Arrese, Anna L. Fracanzani, D. Ben Bashat, K. Lackner, T. Gorfine, S. Kadosh, R. Oren, M. Halperin, L. Hayardeny, R. Loomba, S. Friedman, M. Abdelmalek, F. Angelico, M. Angelico, J. P. Arancibia, E. Bardou-Jacquet, F. Barrera, C. F. Barish, Y. Baruch, Z. Ben-Ari, T. Berg, M. Bourliere, J. Boursier, E. Broide, M. Carmiel, D. S. Denham, L. Di Cesare, D. L. Dumitrascu, A. Francis, S. Gawrieh, M. S. González- Huezo, P. Hillon, A. Iracheta, Z. Kayali, L. Kupcinskas, G. Lau, L. Serfaty, A. Le Cleach, C. Loguercio, M. Manns, B. I. Martinez Saldivar, E. A. Mena, L. A. Morales Garza, J. M. Neutel, L. Nikoleishvili, M. Noureddin, R. Pais, A. H. Paredes, M. Paredes, R. Peters Watkins, A. Picardi, M. Pirisi, G. P. Jofre, L. Preotescu, T. Saadi, D. Samuel, J. F. Sánchez Avila, I. Schiefke, O. Shibolet, M. S. Siddiqui, G. Torres-Mendoza, J. F. Trotter, E. Tsai, E. C. Verna, E. Zuckerman, D. Zur, Arun J. Sanyal
Journal: Nature Medicine (2021)
p113 isoform encoded by CUX1 circular RNA drives tumor progression via facilitating ZRF1/BRD4 transactivation
Authors: Feng Yang, Anpei Hu, Yanhua Guo, Jianqun Wang, Dan Li, Xiaojing Wang, Shikai Jin, Boling Yuan, Shuang Cai, Yi Zhou, Qilan Li, Guo Chen, Haiyang Gao, Liduan Zheng, Qiangsong Tong
Journal: Molecular Cancer (2021)

Abstract Background Metabolic reprogramming sustains tumorigenesis and aggressiveness of neuroblastoma (NB), the most common extracranial malignancy in childhood, while underlying mechanisms and therapeutic approaches still remain elusive. Methods Circular RNAs (circRNAs) were validated by Sanger sequencing. Co-immunoprecipitation, mass spectrometry, chromatin immunoprecipitation (ChIP) sequencing, and RNA sequencing assays were applied to explore protein interaction and target genes. Gene expression regulation was observed by ChIP, dual-luciferase reporter, real-time quantitative RT-PCR, and western blot assays. Gain- and loss-of-function studies were performed to observe the impacts of circRNA-encoded protein and its partners on the lipid metabolism, mitochondrial activity, growth, invasion, and metastasis of NB cells. Results A novel 113-amino acid protein (p113) of CUT-like homeobox 1 ( CUX1 ) was identified in NB cells treated by serum deprivation. Further validating studies revealed that nuclear p113 was encoded by circRNA of CUX1 , and promoted the lipid metabolic reprogramming, mitochondrial activity, proliferation, invasion, and metastasis of NB cells . Mechanistically, p113 interacted with Zuotin-related factor 1 (ZRF1) and bromodomain protein 4 (BRD4) to form a transcriptional regulatory complex, and mediated the transactivation of ZRF1/BRD4 in upregulating ALDH3A1 , NDUFA1 , and NDUFAF5 essential for conversion of fatty aldehydes into fatty acids, fatty acid β-oxidation, and mitochondrial complex I activity. Administration of an inhibitory peptide blocking p113-ZRF1 interaction suppressed the tumorigenesis and aggressiveness of NB cells. In clinical NB cases, high expression of p113 , ZRF1 , or BRD4 was associated with poor survival of patients. Conclusions These results indicate that p113 isoform encoded by CUX1 circular RNA drives tumor progression via facilitating ZRF1/BRD4 transactivation.
325P Trends of primary tumor resection in de novo metastatic breast cancer: The experience of a Mexican center
Authors: F.A. Gonzalez-Mondellini, M.A. Acosta-Sandoval, A. Aranda-Gutierrez, A.S. Ferrigno, M. Roman-Zamudio, M.I. Torres-Leal, A. Becerril-Gaitan, B.F. Vaca-Cartagena, R. Ortiz-López, H.M. Diaz-Perez, C. Villarreal-Garza
Journal: Annals of Oncology (2021)
531P Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Preliminary results of the investigator initiated phase II BEAVER trial
Authors: A. Rose, O. Ayodele, S. Genta, T. Pimentel Muniz, D.C. Kelly, K. Hodgson, I. King, T. Stockley, T. Pugh, Z. Saeed Kamil, M.O. Butler, F.A. Shepherd, P. Bedard, N. Leighl, A.R. Abdul Razak, A.R. Hansen, S. Saibil, D.W. Cescon, L.L. Siu, A. Spreafico
Journal: Annals of Oncology (2021)
Atherosclerosis is a major human killer and non-resolving inflammation is a prime suspect
Authors: Gabrielle Fredman, Katherine C MacNamara
Journal: Cardiovascular Research (2021)

The resolution of inflammation (or inflammation-resolution) is an active and highly coordinated process. Inflammation-resolution is governed by several endogenous factors, and specialized pro-resolving mediators (SPMs) are one such class of molecules that have robust biological function. Non-resolving inflammation is associated with a variety of human diseases, including atherosclerosis. Moreover, non-resolving inflammation is a hallmark of ageing, an inevitable process associated with increased risk for cardiovascular disease. Uncovering mechanisms as to why inflammation-resolution is impaired in ageing and in disease and identifying useful biomarkers for non-resolving inflammation are unmet needs. Recent work has pointed to a critical role for balanced ratios of SPMs and pro-inflammatory lipids (i.e. leucotrienes and/or specific prostaglandins) as a key determinant of timely inflammation resolution. This review will focus on the accumulating findings that support the role of non-resolving inflammation and imbalanced pro-resolving and pro-inflammatory mediators in atherosclerosis. We aim to provide insight as to why these imbalances occur, the importance of ageing in disease progression, and how haematopoietic function impacts inflammation-resolution and atherosclerosis. We highlight open questions regarding therapeutic strategies and mechanisms of disease to provide a framework for future studies that aim to tackle this important human disease.
Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial
Authors: Claus Bachert, Joseph K. Han, Martin Y. Desrosiers, Philippe Gevaert, Enrico Heffler, Claire Hopkins, Jody R. Tversky, Peter Barker, David Cohen, Claire Emson, Ubaldo J. Martin, Vivian H. Shih, Sofia Necander, James L. Kreindler, Maria Jison, Viktoria Werkström
Journal: Journal of Allergy and Clinical Immunology (2021)
E. coli enhance colonization resistance against Salmonella Typhimurium by competing for galactitol, a context-dependent limiting carbon source
Authors: Claudia Eberl, Anna S Weiss, Lara M Jochum, Abilash Chakravarthy Durai Raj, Diana Ring, Saib Hussain, Simone Herp, Chen Meng, Karin Kleigrewe, Michael Gigl, Marijana Basic, Bärbel Stecher
Journal: Cell Host & Microbe (2021)
Abstract 526: Oral And Intravenous Anti-thrombotic Activities Of F 16618, A New Selective Par1 Antagonist With Minor Risk Of Bleeding
Authors: Robert Letienne, Michel Perez, Florence Nadal-Wollbold, Bruno Le Grand
Journal: Circulation (2007)

F 16618 is a new phenyl-pentadienoyl derivative which competitively antagonizes PAR1 giving a prevention in vitro against human platelet aggregation. The main goal of the present study was to investigate the anti-thrombotic effects of F 16618 in two models of platelet aggregation-induced arterial thrombosis: an arteriovenous shunt in anesthetized rats and a photochemical-induced carotid artery thrombosis in anesthetized guinea-pigs. Firstly, a shunt was placed between the right jugular vein and the left carotid artery using polyethylene catheters. The kinetics of thrombus formation were assessed by a thermic probe fixed in the middle of the shunt. F 16618 was administered by gavage 15 min before anesthesia. F 16618 dose-dependently increased the occlusion time from 10 to 80 mg/kg, p.o. The first effective dose was 20 mg/kg and the maximal response was found at 40 mg/kg (54 ± 14 %, P &lt; 0.001 vs. vehicle). In addition, 29 % of the shunts remained open 20 min after unclamping in presence of F 16618 (40 mg/kg, n = 7). Similarly, a high dose of F 16618 administered i.v. significantly delayed the occlusion time (29 ± 8 %, P &lt; 0.05) without any significant effect on the tail bleeding time (358 ± 26 sec in the presence of F 16618 vs 397 ± 38 sec in the presence of vehicle). Secondly, the intravenous activity of F 16618 (from 40 μg/kg to 630 μg/kg) was investigated in a model based on the photochemical reaction between Rose Bengal and trans-illuminated green light to induce a transluminal thrombus in a guinea-pig carotid artery. F 16618 was administered as bolus over 2 min before Rose Bengal administration, followed by a constant infusion over 15 min immediately after the source of light was turned on. F 16618 at 80 μg/kg only tended to increase the occlusion time (29 ± 36 % vs. vehicle). From the dose of 160 μg/kg, F 16618 significantly prolonged this occlusion time and the maximal effect was obtained with 320 μg/kg (bolus and infusion, 112 ± 36 %, P &lt; 0.001 vs. vehicle). Collectively, the results demonstrate that F 16618, a new PAR1 antagonist, dose-dependently prevents platelet-induced arterial thrombosis with minor risk of bleeding by both single intravenous or oral administration.
818TiP Balstilimab alone or in combination with zalifrelimab as second-line treatment for patients with previously treated recurrent/metastatic cervical cancer (R/M CC): A randomized, placebo-controlled phase II trial (RaPiDS/GOG-3028)
Authors: L. Randall, D. O'Malley, C. Gunderson Jackson, R.L. Coleman, J. Hays, K.N. Moore, R.W. Naumann, R. Rocconi, B. Slomovitz, K.S. Tewari, M. Ancukiewicz, W.I. Ortuzar Feliu, B.J. Monk
Journal: Annals of Oncology (2021)
1173P Induction osimertinib in EGFR-mutant stage IIIA/B NSCLC
Authors: W. Kian, L.C. Roisman, J. Dudnik, L. Chernomordikov, A.M. Allen, B. Corn, E. Dudnik, S.K. Rosenberg, M. Zemel, K. Lavrenkov, N. Peled
Journal: Annals of Oncology (2021)
Epigenetic encoding, heritability and plasticity of glioma transcriptional cell states
Authors: Ronan Chaligne, Federico Gaiti, Dana Silverbush, Joshua S. Schiffman, Hannah R. Weisman, Lloyd Kluegel, Simon Gritsch, Sunil D. Deochand, L. Nicolas Gonzalez Castro, Alyssa R. Richman, Johanna Klughammer, Tommaso Biancalani, Christoph Muus, Caroline Sheridan, Alicia Alonso, Franco Izzo, Jane Park, Orit Rozenblatt-Rosen, Aviv Regev, Mario L. Suvà, Dan A. Landau
Journal: Nature Genetics (2021)
1190TiP SKYSCRAPER-03: Phase III, open-label randomised study of atezolizumab + tiragolumab vs durvalumab in patients with locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) who have not progressed after platinum-based concurrent chemoradiation (cCRT)
Authors: R. Dziadziuszko, M-J. Ahn, K.A. Kelly, S. Popat, H. Wakelee, A-M. Baird, I.A. Rooney, M. Afshari, E.S. Yao, Z. Zhang, H. Kuriki, N.S. Patil, X. Wen, J.D. Bradley
Journal: Annals of Oncology (2021)
549P Results of a first-in-human study of the ProTide thymidylate synthase inhibitor NUC-3373, in patients with advanced solid tumours (NuTide:301)
Authors: P. Spiliopoulou, F. Kazmi, F. Aroldi, J. Holmes, J. Graham, T. Holmes, S. Lord, G. Veal, C. Qi, V.M. Coyle, T.R.J. Evans, S. Blagden
Journal: Annals of Oncology (2021)
Abstract 3290: Increased Type 5 Adenylyl Cyclase Expression Mediates Chronic Catecholamine Stress via Increases in Oxidative Stress and Down-regulation of MnSOD
Authors: Lo Lai, Lin Yan, Che-Lin Hu, Shumin Gao, Kosaku Iwatsubo, Yoshihiro Ishikawa, Junichi Sadoshima, Stephen F Vatner, Dorothy E Vatner
Journal: Circulation (2009)

Since knocking out (KO) type 5 adenylyl cyclase (AC5) has been shown to be protective against cardiac stress with chronic high dose of isoproterenol (ISO), we hypothesized that the effects of trans...
1637P Unintended consequences for an integrated oncology ecosystem from COVID adaptations
Authors: P. Bredin, C. Murphy, R.T. O'Dwyer, R. Keogh, A. Doolan, E. Duignan, A. Jones, M.A. Santos, K. Egan, A. Murphy, J. Naidoo, P. Morris, B. Hennessy, L. Grogan, O.S. Breathnach
Journal: Annals of Oncology (2021)
Broad‐Spectrum Antiviral Peptides and Polymers
Authors: Agnès Kuroki, Joyce Tay, Guan Huei Lee, Yi Yan Yang
Journal: Advanced Healthcare Materials (2021)

As the human cost of the pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still being witnessed worldwide, the development of broad-spectrum antiviral agents against emerging and re-emerging viruses is seen as a necessity to hamper the spread of infections. Various targets during the viral life-cycle can be considered to inhibit viral infection, from viral attachment to viral fusion or replication. Macromolecules represent a particularly attractive class of therapeutics due to their multivalency and versatility. Although several antiviral macromolecules hold great promise in clinical applications, the emergence of resistance after prolonged exposure urges the need for improved solutions. In the present article, the recent advancement in the discovery of antiviral peptides and polymers with diverse structural features and antiviral mechanisms is reviewed. Future perspectives, such as, the development of virucidal peptides/polymers and their coatings against SARS-CoV-2 infection, standardization of antiviral testing protocols, and use of artificial intelligence or machine learning as a tool to accelerate the discovery of antiviral macromolecules, are discussed.
1221P Outcomes of EGFR-mutant NSCLC patients with de novo brain metastases by upfront treatment
Authors: J. Ma, Y. Li, G.G.Y. Lai, E-H. Tan, W.D.T. Lim, M-K. Ang, Q.S. Ng, R. Kanesvaran, A. Jain, T. Rajasekaran, K.W. Fong, T.R. Siow, A. Thiagarajan, S.P. Yap, S.H.B. Chia, W.L. Ng, D.S.W. Tan, S.H. Tan, W.L. Tan, K.L.M. Chua
Journal: Annals of Oncology (2021)
Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance
Authors: Sue Pavord, Beverley J Hunt, Daniel Horner, Susan Bewley, Justine Karpusheff
Journal: BMJ (2021)

### What you need to know

The UK vaccination programme has prevented thousands of deaths from infection with SARS-CoV-2, but has been accompanied by new vaccine related complications. The most serious of these is a novel disorder, described as vaccine induced immune thrombocytopenia and thrombosis (VITT). This immune mediated condition is caused by development of pathological anti-platelet factor 4 (PF4) antibodies following vaccination against covid-19, which leads to intense activation of platelets and the coagulation system. The subsequent clinical syndrome often presents with life threatening thrombosis and secondary haemorrhage, which are challenging to manage in the context of new biochemical coagulopathy.

This article summarises the most recent recommendations from the rapid covid-19 guideline produced by the National Institute for Health and Care Excellence (NICE).1

NICE recommendations are based on systematic reviews of best available evidence. This guideline was developed using an interim process and methods for guidelines developed in response to health and social care emergencies. These included convening an independent advisory expert panel, scoping, identifying, and reviewing …
1545P Initial presentation of sarcomas in adult patients from private and public health insurance systems in Brazil: A single center analysis
Authors: C.S.S. Filho, M.P.S. Aruquipa, M.R.S. Costa, S.A. Nakagawa, F.D. Costa, C.A. Mello, S. Aguiar, F.A.B. Campos
Journal: Annals of Oncology (2021)
268P Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple-negative, EGFR positive breast cancer: A multicenter single arm phase II trial [SAKK 24/14]
Authors: A. Wicki, C. Mamot, U. Hasler-Strub, S. Riniker, Q. Li, L. Holer, D. Baertschi, K. Zaman, R. von Moos, K.J. Dedes, U. Novak, A. Bodmer, R. Ritschard, E. Obermann, C.J. Ackermann, V. Membrez-Antonioli, U. Zuerrer, C.B. Caspar, C. Rochlitz, R.C. Winterhalder
Journal: Annals of Oncology (2021)
Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial
Authors: Koray Tascilar, Melanie Hagen, Arnd Kleyer, David Simon, Michaela Reiser, Axel J Hueber, Bernhard Manger, Matthias Englbrecht, Stephanie Finzel, Hans-Peter Tony, Florian Schuch, Stefan Kleinert, Joerg Wendler, Monika Ronneberger, Camille P Figueiredo, Jayme F Cobra, Martin Feuchtenberger, Martin Fleck, Karin Manger, Wolfgang Ochs, Matthias Schmitt-Haendle, Hanns-Martin Lorenz, Hubert Nuesslein, Rieke Alten, Klaus Kruger, Joerg Henes, Georg Schett, Juergen Rech
Journal: The Lancet Rheumatology (2021)
Early computed tomography coronary angiography in patients with suspected acute coronary syndrome: randomised controlled trial
Authors: Alasdair J Gray, Carl Roobottom, Jason E Smith, Steve Goodacre, Katherine Oatey, Rachel O’Brien, Robert F Storey, Nick Curzen, Liza Keating, Attila Kardos, Dirk Felmeden, Robert J Lee, Praveen Thokala, Steff C Lewis, David E Newby
Journal: BMJ (2021)

Abstract Objectives To establish if the use of early computed tomography (CT) coronary angiography improves one year clinical outcomes in patients presenting to the emergency department with acute chest pain and at intermediate risk of acute coronary syndrome and subsequent clinical events. Design Randomised controlled trial. Setting 37 hospitals in the UK. Participants Adults with suspected or a provisional diagnosis of acute coronary syndrome and one or more of previous coronary heart disease, raised levels of cardiac troponin, or abnormal electrocardiogram. Interventions Early CT coronary angiography and standard of care compared with standard of care only. Main outcome measures Primary endpoint was all cause death or subsequent type 1 or 4b myocardial infarction at one year. Results Between 23 March 2015 and 27 June 2019, 1748 participants (mean age 62 years (standard deviation 13), 64% men, mean global registry of acute coronary events (GRACE) score 115 (standard deviation 35)) were randomised to receive early CT coronary angiography (n=877) or standard of care only (n=871). Median time from randomisation to CT coronary angiography was 4.2 (interquartile range 1.6-21.6) hours. The primary endpoint occurred in 51 (5.8%) participants randomised to CT coronary angiography and 53 (6.1%) participants who received standard of care only (adjusted hazard ratio 0.91 (95% confidence interval 0.62 to 1.35), P=0.65). Invasive coronary angiography was performed in 474 (54.0%) participants randomised to CT coronary angiography and 530 (60.8%) participants who received standard of care only (adjusted hazard ratio 0.81 (0.72 to 0.92), P=0.001). There were no overall differences in coronary revascularisation, use of drug treatment for acute coronary syndrome, or subsequent preventive treatments between the two groups. Early CT coronary angiography was associated with a slightly longer time in hospital (median increase 0.21 (95% confidence interval 0.05 to 0.40) days from a median hospital stay of 2.0 to 2.2 days). Conclusions In intermediate risk patients with acute chest pain and suspected acute coronary syndrome, early CT coronary angiography did not alter overall coronary therapeutic interventions or one year clinical outcomes, but reduced rates of invasive angiography while modestly increasing length of hospital stay. These findings do not support the routine use of early CT coronary angiography in intermediate risk patients with acute chest pain and suspected acute coronary syndrome. Trial registration ISRCTN19102565 , NCT02284191 .
898P Locoregional vs. distant relapse: Impact on survival in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immunotherapy
Authors: E.L. Alouani, L. Piram, L. Chaltiel, S. Rigal, J-P. Delord, C. Bastien, C.A. Gomez-Roca
Journal: Annals of Oncology (2021)
258P Analysis of patients (pts) without an initial triple-negative breast cancer (TNBC) diagnosis (Dx) in the phase III ASCENT study of sacituzumab govitecan (SG) in brain metastases-negative (BMNeg) metastatic TNBC (mTNBC)
Authors: J. O'Shaughnessy, A. Brufsky, H.S. Rugo, S.M. Tolaney, S. Diab, K. Punie, S. Sardesai, E. Hamilton, D. Loirat, T.A. Traina, R. Leon-Ferre, S.A. Hurvitz, K. Kalinsky, A. Bardia, S. Henry, I. Mayer, Q. Hong, S. Phan, J. Cortés
Journal: Annals of Oncology (2021)
54P Assessment of EU4 laboratory readiness for FGFR2 fusion testing of cholangiocarcinoma by NGS
Authors: M. Sciortino, N. Atkey, B. Bisaro, G. Courtois, N. Holtkamp, J. Iparraguirre, B. Holt, P.V. Ricelli, S. Munksted, J. Clark
Journal: Annals of Oncology (2021)
292P Serum thymidine kinase 1 activity in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first-line with ribociclib (R) and letrozole (L) in the BioItaLEE trial
Authors: L. Malorni, M. De Laurentiis, G. Bianchini, A. Zambelli, F. Puglisi, G.V. Bianchi, L. Del Mastro, I. Paris, F. Montemurro, G. Allegrini, M.A. Colleoni, S. Tamberi, C. Zamagni, M.E. Cazzaniga, M. Orditura, V. Guarneri, D. Castelletti, M. Benelli, M. Di Marino, G. Arpino
Journal: Annals of Oncology (2021)
1679P A double-blind, placebo-controlled, randomized phase IIa trial, evaluating the effect of curcumin for the treatment of cancer anorexia-cachexia syndrome in patients with stage III-IV head and neck cancer (CurChexia)
Authors: T. Thambamroong, S. Saichaemchan, K. Seetalarom, N. Prasongsook
Journal: Annals of Oncology (2021)
Credible signalling and social bonds: Ultimately drawing on the same idea
Authors: Patrick Kennedy, Andrew N Radford
Journal: Behavioral and Brain Sciences (2021)

Abstract The hypotheses in both target articles rely implicitly on much the same logic. For a “social-bonding” device to make sense, there must be an underlying reason why an otherwise-arbitrary behaviour sustains alliances – namely, credible signals of one's value to partners. To illustrate our points, we draw on the parallels with supposed bonding behaviours in nonhuman animals.